This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Clinical Trial Data Show Substantial Improvement With Eculizumab (Soliris®) In Patients With STEC-HUS

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of 28-week data from all enrolled patients in a multi-center trial of eculizumab (Soliris ®) in patients who developed Shiga-toxin-producing E. coli hemolytic uremic syndrome (STEC-HUS) during an outbreak in Germany from May 2011 to July 2011. In the study, eculizumab therapy was associated with rapid and sustained clinical improvements in thrombotic microangiopathy (TMA) and systemic organ complications. The study met its primary endpoint of global assessment of efficacy at 8 weeks with 94% of patients achieving a complete or partial response in systemic TMA and vital organ involvement. Key secondary endpoints were also met with high clinical and statistical significance, including global assessment of efficacy at 28 weeks as well as improvement in hematologic, renal and neurologic functions. Preliminary findings from an exploratory post hoc, matched-control analysis of patients with severe STEC-HUS receiving eculizumab versus other patients who received current best supportive care during the German epidemic were also reported, and showed that eculizumab treatment was associated with consistently higher rates of renal and neurological function improvement at weeks 8 and 28. 1

The eculizumab 28-week data, presented today at Kidney Week 2012, the annual meeting of the American Society of Nephrology (ASN) in San Diego, were consistent with previously presented interim data, in which 148 of the overall 198 patients with STEC-HUS treated with eculizumab were reported to have experienced substantial improvement in systemic TMA and vital organ complications 8 weeks following treatment initiation with eculizumab. 2

“In the study, patients had a robust response to eculizumab therapy. Patients achieved a substantial improvement in systemic TMA and vital organ involvement as early as 8 weeks, which was sustained through 28 weeks,” said Rolf Stahl, M.D., Chairman, Department of Nephrology, University Hospital Hamburg-Eppendorf UKE and lead investigator of the trial. “The rapid, sustained reduction in TMA and reversal of organ damage with eculizumab supports the important role of uncontrolled complement activation in the severe morbidities associated with STEC-HUS.”

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs